Stockreport

Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF other autoimmune candidate IMVT-1402 inches closer to a pivotal trial later this year. The results for batoclimab include “strong response rates” following an injectio [Read more]